{
  "first_published_at": "2011-09-07", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON128959", 
  "title": "Pseudoephedrine and ephedrine: update on managing risk of misuseQ", 
  "tags": "{\"parsed_therapeutic\": [\"ear-nose-throat\", \"respiratory-disease-allergy\"], \"Therapeutic area:\": [\"Ear, nose and throat\", \"Respiratory disease and allergy\"]}", 
  "_document_number": 140, 
  "label": null, 
  "icon": null, 
  "therapeutic_area": [
    "ear-nose-throat", 
    "respiratory-disease-allergy"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Pseudoephedrine and ephedrine: update on managing risk of misuse</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: September 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Implementation of measures to regulate sales, together with the additional voluntary actions overseen by the profession, has made an important contribution to managing the risk of misuse of the nasal decongestants pseudoephedrine and ephedrine in the illicit manufacture of the Class A controlled drug methylamphetamine-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Pseudoephedrine and ephedrine are medicines used as nasal decongestants, which are available from pharmacies. Between 2007 and 2008, we introduced restrictions on their use because of concern that medicines containing these active substances could be used in the illicit manufacture of the Class A controlled drug methylamphetamine.</p><h2>Sales restrictions</h2><p>Since April 2008, after public consultation and following advice from the Commission on Human Medicines (CHM), the following sales restrictions have been in place:</p><ul>\r\n\t\t\t<li>It is illegal to sell or supply any product that contains more than 720 mg pseudoephedrine or 180 mg ephedrine without a prescription</li>\r\n\t\t\t<li>It is illegal to sell or supply a combination of products that between them add up to more than 720 mg pseudoephedrine or 180 mg ephedrine without a prescription</li>\r\n\t\t\t<li>It is illegal to sell or supply a product that contains pseudoephedrine and a product that contains ephedrine in one transaction</li></ul><p>Furthermore, the <a href=\"http://www.rpharms.com/home/home.asp\" target=\"_blank\">Royal Pharmaceutical Society</a> advises that the sale and supply of these products must be made by a pharmacist or suitably trained pharmacy staff under the supervision of a pharmacist.</p><p>This information was published in the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087857\">October 2008 issue of Drug Safety Update</a>.</p><p>CHM has continually reviewed these measures and the impact on containing the potential problem of misuse (see Drug Safety Updates <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087910\">September 2009</a> and <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON093847\">September 2010</a>).</p><h2>Impact of restrictions: 2011 review</h2><p>Between July 2010 and July 2011 there was one report in UK of limited misuse of these medicines. The evidence suggests that the restrictions are continuing to help manage the risk of misuse. Further information is available in our report: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON126277\">Pseudoephedrine and ephedrine: Managing the risk of misuse of medicines - July 2011 review</a>).</p><p>Implementation of measures to regulate sales, together with the additional voluntary actions overseen by the profession, has made an important contribution to managing the risk of misuse. The CHM commended the pharmacy profession for their substantial contribution to managing the risk of misuse and recommended that existing levels of monitoring, education, and awareness measures by pharmacists should be maintained.</p><p><strong>Further information:</strong></p><p>BNF section 3.10 <a href=\"http://bnf.org/bnf/bnf/61/20311.htm?q=pseudoephedrine&t=search&ss=text&p=1\" target=\"_blank\">Systemic nasal decongestants</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Sept 2011 vol 5 issue 2: H2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Pseudoephedrine and ephedrine are medicines used as nasal decongestants, which are available from pharmacies. Between 2007 and 2008, we introduced restrictions on their use because of concern that medicines containing these active substances could be used in the illicit manufacture of the Class A controlled drug methylamphetamine.</p><h2>Sales restrictions</h2><p>Since April 2008, after public consultation and following advice from the Commission on Human Medicines (CHM), the following sales restrictions have been in place:</p><ul>\r\n\t\t\t<li>It is illegal to sell or supply any product that contains more than 720 mg pseudoephedrine or 180 mg ephedrine without a prescription</li>\r\n\t\t\t<li>It is illegal to sell or supply a combination of products that between them add up to more than 720 mg pseudoephedrine or 180 mg ephedrine without a prescription</li>\r\n\t\t\t<li>It is illegal to sell or supply a product that contains pseudoephedrine and a product that contains ephedrine in one transaction</li></ul><p>Furthermore, the <a href=\"http://www.rpharms.com/home/home.asp\" target=\"_blank\">Royal Pharmaceutical Society</a> advises that the sale and supply of these products must be made by a pharmacist or suitably trained pharmacy staff under the supervision of a pharmacist.</p><p>This information was published in the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087857\">October 2008 issue of Drug Safety Update</a>.</p><p>CHM has continually reviewed these measures and the impact on containing the potential problem of misuse (see Drug Safety Updates <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087910\">September 2009</a> and <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON093847\">September 2010</a>).</p><h2>Impact of restrictions: 2011 review</h2><p>Between July 2010 and July 2011 there was one report in UK of limited misuse of these medicines. The evidence suggests that the restrictions are continuing to help manage the risk of misuse. Further information is available in our report: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON126277\">Pseudoephedrine and ephedrine: Managing the risk of misuse of medicines - July 2011 review</a>).</p><p>Implementation of measures to regulate sales, together with the additional voluntary actions overseen by the profession, has made an important contribution to managing the risk of misuse. The CHM commended the pharmacy profession for their substantial contribution to managing the risk of misuse and recommended that existing levels of monitoring, education, and awareness measures by pharmacists should be maintained.</p><p><strong>Further information:</strong></p><p>BNF section 3.10 <a href=\"http://bnf.org/bnf/bnf/61/20311.htm?q=pseudoephedrine&amp;t=search&amp;ss=text&amp;p=1\" target=\"_blank\">Systemic nasal decongestants</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Sept 2011 vol 5 issue 2: H2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-09-01", 
  "date_last_modified": "2011-09-07", 
  "_assets": [], 
  "_item_id": 140, 
  "summary": "", 
  "body": "Article date: September 2011\n\nPseudoephedrine and ephedrine are medicines used as nasal decongestants, which are available from pharmacies. Between 2007 and 2008, we introduced restrictions on their use because of concern that medicines containing these active substances could be used in the illicit manufacture of the Class A controlled drug methylamphetamine.\n\n## Sales restrictions\n\nSince April 2008, after public consultation and following advice from the Commission on Human Medicines (CHM), the following sales restrictions have been in place:  \n  \n  * It is illegal to sell or supply any product that contains more than 720 mg pseudoephedrine or 180 mg ephedrine without a prescription  \n  * It is illegal to sell or supply a combination of products that between them add up to more than 720 mg pseudoephedrine or 180 mg ephedrine without a prescription  \n  * It is illegal to sell or supply a product that contains pseudoephedrine and a product that contains ephedrine in one transaction  \n  \nFurthermore, the [Royal Pharmaceutical Society](http://www.rpharms.com/home/home.asp) advises that the sale and supply of these products must be made by a pharmacist or suitably trained pharmacy staff under the supervision of a pharmacist.\n\nThis information was published in the [October 2008 issue of Drug Safety Update](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087857).\n\nCHM has continually reviewed these measures and the impact on containing the potential problem of misuse (see Drug Safety Updates [September 2009](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087910) and [September 2010](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON093847)).\n\n## Impact of restrictions: 2011 review\n\nBetween July 2010 and July 2011 there was one report in UK of limited misuse of these medicines. The evidence suggests that the restrictions are continuing to help manage the risk of misuse. Further information is available in our report: [Pseudoephedrine and ephedrine: Managing the risk of misuse of medicines - July 2011 review](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON126277)).\n\nImplementation of measures to regulate sales, together with the additional voluntary actions overseen by the profession, has made an important contribution to managing the risk of misuse. The CHM commended the pharmacy profession for their substantial contribution to managing the risk of misuse and recommended that existing levels of monitoring, education, and awareness measures by pharmacists should be maintained.\n\nFurther information:\n\nBNF section 3.10 [Systemic nasal decongestants](http://bnf.org/bnf/bnf/61/20311.htm?q=pseudoephedrine&t=search&ss=text&p=1)\n\n \n\nArticle citation: Drug Safety Update Sept 2011 vol 5 issue 2: H2.\n"
}